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Recent studies (I-7) have demonstrated thattimely admin- 
istration of thrombolytic therapy decreases myocardial in- 
farct size, lessens the incidence of congestive heart failure 
aud improves hort- and long-term survival. Because of 
oveiwhehning evidence of clinicA benefit provided by reper- 
fusion therapy, several placebo-c )ntrolled trials (6,840) 
were terminated before their planued end point. However. it
is well recognized that thrombolytic agents have the poten- 
tial for causing serious and even life-threatening complica- 
tions. Therefore, appropriate patient selection is critical so 
that he maximal number of patients with myocardial infarc- 
tion can benefit from this important therapeutic option with 
minimal side effects. 
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61990 by fhe American College of Cardiology 
munity and the lay press, little attention has been paid to the 
percent of patients with infarction who qualify as appropri- 
ate candidates for treatment. Table I outlines the results of 
several studies that evaluated the proportion ofpatients with 
myocardial infarction eligible for thrombolytic therapy ac- 
cording to conventional guidelines. Two separate centers 
cipated in the Thrombolysis in ocardial 
) study found that only 9% 14% of 
patients with acute myocardial infarction at their institutions 
met the inclusion criteria established by the National Heart, 
Lung. and Blood Institute. The primary reasons for ineligi- 
bility were chest pain duration >4 b, age >75 years and an 
electrocardiogram (ECG) that did not qualify the patient for 
treatment. Studies (3,13-17) that expanded the time frame to 
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TabIe 1. Proportion of Patients With Acute Myocardial Infarction that nearly 75% of patients with myocardial ~afa~ctio~ d  not 
Elicible for Thrombolvtic Therapy in Previous Trials satisfy the current guidelines for thrombolytic therapy. 
% Excluded 
Study % Eligible 
Because of Time 
From Symptom 
Onset 
Because 
of Age 
Doorey et ai. t 1 i 1 9 
Cragg et al. (12) 14 
Sainsous et al. (13) I.5 
Murray et al. (14) 9 
Khaja et al, (151 18 
ISAM Study Group (3) 23 
Weaver et al. (16) 20 
Althouse et al. (171 25 
Jaggers et al. (18) 51 
ASSET (5) 38 
GJSSI (4) 37 
71 10 
18 31 
57 17 
39 10 
75 NA 
37 20 
16 35 
25 31 
I3 7 
46 5 
32 Y.” 
ASSET = Angl~candinavian Study of Early Throm~lysis: GJSSJ = 
Gruppo ltaliano per lo Studio deila Strepto~hinasi nei~lnfa~o Mio~rdico; 
ISAM = intravenous Streptokinase in Acute Myocardial Infarction trial: 
NA = not applicable. 
6 h were able to enroll up to 25% of patients with myoc~dial 
infarction. Only one study (18) found that approximately 
50% of patients were ligible for thrombolytic herapy. If one 
liberalizes the enrollment criteria to allow treatment of 
patients in the absence of diagnostic ECG changes, the 
percent of eligible patients increases to38%, as seen in the 
Angl~Scandinavian Study of Early Thromboly~s (ASSET) 
trial (5). Interestingly, even though the Gruppo Italian0 per 
lo Studio della Streptochinasi nell*Infarto Miocardico 
(GISSI) trial (4) allowed enrollment up to 12 h from symptom 
onset and did not exclude, the elderly or patients with 
isofated ST segment depression or shock, only 37% of 
patients were eligibIe for treatment. Therefore, it appears 
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ortality rate of eligible vems NQ~e~i~~~~e patients. 
tality rates among patients excluded from thrombolytic rials 
have been far greater than among those ligible for treatment 
(Fig. I) (4,5,12,I~). Cragg et al. (112) analyzed 1,206 ~tient§ 
with acute infarction admitted ts their institution d~riag the 
recruitment period for the TI~I-2~ study. Among the I$% 
of patients with infarction who met eligibility criteria, the 
in-hospital m~~taIity rate was 2.5%. However, the mortality 
rate in 1,013 patients who were ineligible for tbe study 
averaged I$% (p < 0.~1~. Therefore, the criteriaes~blished 
by the National Heart, Lung, and Blood Institute admin- 
istration of thrombolytic drugs may select only a ority of 
patients who represent a low risk group. It has been argued 
that high risk patients are receiving thrombolytic therapy 
outside of investigational protocols. however, deter et al. 
(19) monitored nonprot~ol use of throm~lytic therapy at 
133 North American hospitals between 1987 and 19g9. They 
reported ifferences between the preinfarction characteris- 
tics of groups treated or not treated with thrombolytic drugs. 
Before the index infarction, patients who received tbr~rn~ 
bolytic the~py were signi~cantly younger, less often female 
or diabetic, had a better functional status, used fewer cardiac 
medications and were less likely to have a history of prior 
infarction or prior angina (p < 0.005) compared with patients 
who were not treated. 
Therefore, at present, both cl~aical nd iav~stigational 
use of thrombolytic herapy has been limited to a relatively 
low risk group of patients. Even the GISSI trial (4), which 
treated ;dgh risk subsets uch as the elderly and those in 
cardiogenic shock, demonstrated a relatively high mortality 
rate in patients excluded primarily on the basis of low 
suspicion for my~a~ial infarction or presenting >I2 h from 
symptom onset. Accordingly, one must be cautious in ex- 
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Figure 1. Mortality rates of patients 
considered ligible (o bars, treated 
and control group morality combined~ 
and ineligible (hatched bars) for partic- 
ipation in four thrombolytic trials. In 
general, patients elected for throm- 
bolytic therapy are a low risk group. 
Patients considered ineligible for 
thrombolytic ~erapy constitute a high 
risk group in which reclusion ther- 
apy may have ;cn even greater impact 
on mortality. ASSET = Anglo-Scandi- 
navian Study of Early Thrombolysis 
(5); GISSI = Ciruppo Italiano per lo 
Studio della Streptochinasi nell’rnfa~o 
~i~ardico (4); hIIT = ~y~ardial 
Infarction Triage and Intervention trial 
(16); TIM1 = Thrombolysis in Myocar- 
dial Infarction trial (12). 
majority of patients with myoc 
are eligible for thr 
medical records for 75 acute care ho 
40,500 patients with myocardial infarction recei 
hospitalized patients with the discharge diagnosis of myo- 
cardial infarction (23). only IO% may receive tbrombolytic 
therapy. Considering the demonstrated lifesaving potential 
of thrombolytic therapy, it is important to determine why so 
few patients are being treated. 
The problem may relate in part to physician a 
thrombolytic therapy for myocardial infarction. 
(24) at Duke University found that medical specialty type 
had a major impact on physician use of thrombolytic ther- 
apy. Although 80% of cardiologists were using such therapy 
at the time of their survey, only 60% of internal medicine 
specialists and only 33% of general practitioners would 
consider employing thrombolytic agents. Younger physi- 
cians and those who practiced at large academic institutions 
with available catheterization laboratories were much more 
likely to use thrombolytic drugs. However, the majority of 
patients with infarction are not hospitalized at large aca- 
demic institutions. The National Hospital Discharge Survey 
(25) and Medicare database (26) agree that the majority of 
patients are treated at nonteaching hospitals with <300 beds. 
Although it is difficult to substantiate, a cardiologist, if 
available, is not the primary care physician, but may serve 
only as a consultant at many institutions. 
Thus, the foregoing data demonstrate that only a small 
number of patients with myocardial infarction fulfill current 
eligibility criteria for thrombolytic therapy and that many of 
these patients are hospitalized in a setting in which throm- 
and have recently been 
surgery or significant trauma. prolonged cardiopulmonary 
resuscitation. any cerebrovascular accident or neoplasm and 
orly controlled hypertension or blood pressure 
or > 110 mm pig diastolic at the time of 
lative contraindications include other 
cardiac or medica isorders that may put the patient at 
increased risk of complications, women of childbearing 
potential, potential for allergic reactions and prior anticoag- 
ulation. 
1t is important to recognize that these exclusion criteria 
have evolved primarily as a result of historical recommen- 
dations, with very little supporting scientific data available. 
Because the majority of clinical trials have excluded patients 
with the foregoing characteristics, it may be very difficult for 
the clinician to accurately assess the risk/benefit ratio for a 
patient with one or more contraindications. Several patient 
groups exist in whom the risk/benefit ratio of thrombolytic 
therapy continues to be controversial. Included in this class 
are patients with inferior myocardial infarction or absence of 
ST segment elevation, patients who present >6 h from 
symptom onset, elderly patients and 0 >se with hyperten- 
sio 
ial i~~~~~~~~~. In the past, considerable 
controversy existed with regard to whether patients with 
inferior infarction benefit from clot dissolution therapy. 
Table 2 demonstrates mortality results from nine placebo- 
controlled trials (2,3,.5-8,29-31) in patients with inferior 
myocardial infarction. Given the low mortality rate in the 
control groups after inferior infarction, it has been difficult to 
achieve a significant improvement in survival with throm- 
226 GRINES AND DEMARIA 
INDICATIONS FOR THROMBOLYTIC THERAPY 
JACC Vol. 16. No. I 
July 1990:223-31 
Table 2. Mortality Rates in Inferior Myocardial Infarction in Previous Trials 
Treated Control 
Study Follow-Up No. 1%) No. 1%) p Value 
Kennedy et al. (21 
Kennedy et al. (81 
Vermeer et al. (29) 
European Coop (30) 
ISAM (3) 
GlSSl (31 l 
ISIS-II (7) 
ASSET 151 
AIMS (6) 
4 wk 
2 wk 
3 mo. 
6 mo. 
7 mo. 
1 yr 
5 wk 
I mo. 
I mo. 
o/71 
51124 
61129 
8169 
461448 
I3712.009 
I 5012.076 
471753 
I l/329 
(0) 
(4.01 
(4.71 
(11.6) 
(10.31 
(6.81 
i7.2) 
(6.3) 
(3.31 
3163 (4.81 0.06 
?/I IO (I.81 0.32 
14038 llO.11 0.09 
I3163 (20.6) 0.16 
611429 (14.21 0.07 
14512.004 (7.2) 0.6 
18512.1 I? (8.8) 0.06 
741754 (9.81 0.01 
261333 (7.8) 0.01 
Pooled 4 lO/6.008 (6.8) 523/6,006 (8.71 0.0001 
AIMS = APSAC Interventional Mortality Study (APSAC = anisoyktted plasminogen streptokinase activator 
complex): ISIS-II = Second International Study of Infarct Survival: European Coop = European Cooperative Study 
Group; other abbreviations as in Table I. 
bolytic therapy. However, these trials demonstrate hat 
although the mortality benefit may be less fo. qatients with 
inferior infarction, thrombolytic treatment is worthwhile in 
most cases. Three recently published stuutes +71 demon- 
strated areduction i  mortality rate that was entirely inde- 
pendent of infarct location. Pooled data involving >12.000 
patients with inferior myocardial infarction (Table 2, Fig. 21 
indicate a reduced mortality rate in the thrombolytic treat- 
ment group (6.8%) compared with the control group (8.7%) 
(p < 0.0001). In no large mortality trial did patients with 
inferior myocardial infarction have a poorer outcome as a 
result of complications of thrombolysis. 
Bates (32) recently reviewed theeffect of thrombolytic 
therapy on left ventricular function in patients with inferior 
myocardial infarction (Table 3). Seven placebo-controlled 
trials, four of which used streptokinase (1,2,8.33) and three 
that used tissue plasminogen activator (9,34,35), demon- 
strated either a trend or a significant difference in left 
ventricular function in favor of patients with inferior infarc- 
tion treated with thrombolytic therapy. The difference in 
ejection fraction between treated and placebo groups ranged 
from 2 percentage points (as seen in the Western Washington 
Intravenous Streptokinase in Acute Myocardial Infarction 
trial [B]) to an improvement of 8 percentage points in the 
report of Simoons et al. (I). Furthermore, several dditional 
trials (36-39) demonstrated a significant improvement in 
infarct zone function after reperfusion therapy of inferior 
infarction. Therefore. in the absence of contraindications, 
we believe patients with acute inferior myocardial infarction 
should undergo thrombolytic reatment. 
Absence of ST segment elevation. Although current rec- 
ommendations require the presence of ST segment eleva- 
tion, one may question whether there is any benefit of 
thrombolytic therapy in the absence of this ECG abnormal- 
ity. Regardless of the clinical findings, one generally does 
not consider administering thrombolytic drugs to a patient 
Q c .OOOl 
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Q < .661 
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e 6- 
Figure 2. Mortality rates in patient subgroups in 
which the risk/benefit ratio has been controversial. 
Pooled data demonstrate a mortality advantage 
after thrombolytic therapy (open bars) compared 
with control (hatched bars) for patients with infe- 
~tor myocardial infarction (MI), elderly patients 
and patients treated between 6 and 24 h after chest 
pain onset. See Tables 2, 5 and 6 for details. 
e 3. Ejection Fraction After inferior 
Previous Trials 
LVEF ($6) 
Study Trealed Control 
Kennedy el al. (2) 52 39 
Kennedy et al. (8) 55 53 
Simoons et al. (1) 57 49 
White et al. (33) 60 55 
Guerci et al. (9) 59 54 
O’Rourke et al. (34) 66 59 
Australia (35) 62 57 
p Value 
0.13 
0.39 
u.05 
0.06 
0.017 
0.10 
Australia = National Heart Foundation of Australia Coronary Thrombof- 
ysis Group; LVEF = left ventricular ejection fraction. 
who presents with an 
substantiated by dat 
but a normal ECG (Table 4). 
with ST segment depressio 
minimal benefit from thro 
in this subgroup. This finding may reflect selection bias, 
whereby only the very sickest patients with ST segment 
depression were thought to be suffering from an acute 
myocardial infarction. 
Lejl bun& branch block. 
bundle branch block may 
difficult to interpret, patients this finding have generally 
been excluded from thrombo trials. Left bundle branch 
block was present in 6% of the patients in the GIlSSB trial (4) 
and there appeared to be little Berence in mortality rate 
between treated and control groups. In contrast, the ISIS-II 
trial (7) found patients who present with chest pain and left 
bundle branch block to be a very high risk group, having a 
Table 4. Mortality in the Absence of ST Segment Elevation in 
Previous Trials 
ECG Study 
No. of Deaths I%) 
Treated Control p Value 
Normal ASSET (5) 71443 (I .6) 131431 (3.0) 0.2 
ISIS-II (7) 31100 (1.2) 61155 (3.9) 0.3 
LBBB GM1 (4) 261325 (X.0) 291336 (8.6) 0.77 
ISIS-II (7) 831419 (19.8) 1021408 (27.7) 0.07 
ST depression GlSSl(4) 46/224 (20.51 371227 (16.3) 0.25 
ISIS-II (7) 107/571 (18.7) 1051566 (18.2) 0.9 
ECG = electrocardiogram: LBBB = left bundle branch block: other 
abbreviations as in Tables I and 2. 
7us Trials 
No. of Deaths t%) 
L xes 
Time Treated Control Saved* p Value 
O-6 h 
Yusuf et al. (40) IO%22 (17.0) Il5/564 (20.0) 3.0 0.12 
GlSSl(4) 49514.865 f 10.2) 623j4.878 (12.8) 2.6 t?.O=Ol 
ISIS-II (7) 30713,729 (8.2) 45813.738 (12.3) 4.1 0. 
Pooled YO7/9.216 (9.8) 1.19619.180 (13.0) 3.2 
6-12 h 
Yusuf et al. (40) 651358 (18.0) 701341 (21.0) 3.0 0.42 
GlSSl(4) 133/985 (13.5) 1341961 (13.9) 0.4 0.77 
ISIS-II (7) 378/3.639 (IO.41 43913,630 (12.1) 1.7 0.02 
Pooled 57614.982 (11.6) 64314.932 (13.0) 1.4 0.03 
12-24 h 
44/354 (12.0) 841383 (220) 10.0 o.ooo7 
lU6/1.224 (8.7) 132/1.227 (10.8) 2.1 0.08 
Pooled 15011.578 (8.7) 216/1.610(11.81 3.1 0.002 
*Number of lives saved per IO3 patients treated: abbreviations as in 
Tables 1 rnd a. 
mortality rate of 28% in the absence of treatment, 19.8% 
er streptokinase and 84% after streptoki 
erefore, in the absence of co~traind~cati 
present with good clinical evidence for my 
but whose ECG manifests left bridge bran 
comsidered for thrombolytic therapy. 
e to treat t. The majority of patients thus far 
denied entry to tkrom ic trials have been exclude 
because of presentation 
rationale for exclusion i 
the belief that by surviving several hours, a patient has 
cted himself or herself to be in a category at a low risk of 
dying. Of the three large studies that addressed this issue, 
two were prospectively conducted (4,7) and one (40) was a 
ective a .alysis of pooled data (Table 5). In these 
three studies, patients who presented late continued to be at 
high risk of dying despite surviving the first several hours of 
infarction. Although the GISSI trial (4) showed minimal 
benefit from thrombolytic therapy, both Yusef et al. (40) and 
the ISIS-II trial (7) reported improved survival in patients 
treated after 6 h. Furthermore, treatment between 12 and 24 
h after symptom onset resulted in an improvement in sur- 
vival similar to that in the earlier treatment group. Pooled 
data from the three studies (4.7,40) indicate a reduced 
mortality rate after thrombolytic therapy in patients who 
present between 6 and 24 h after chest pain onset (Table 5, 
Fig. 2). 
These results were achieved with streptokinase, an agent 
that has been found to be relatively ineffective at achieving 
infarct vessel patency when administered in the late hours of 
infarction (41). Whether the results with stre 
be reproduced and whether alternative thromboiytic drugs 
such as recombinant tissue-type plasminogen activator (rt- 
PA) or anisoylated plasminogen streptokinase activator 
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complex (APSAC) show a similar nr even 
patients presenting after 6 h is the subject of several ongoing 
trials. Therefore, at present he rationale for withholding 
therapy after 6 h is not validated. Until the results of delayed 
repel-fusion trials are available, the routine administration f 
thrombolytic drugs cannot be advocated for patients who 
present late; however, serious consideration should be given 
to any patient with stuttering onset of chest pain or contin- 
ued chest pain beyond the 6 h window. 
expediting early treatment. Efforts to provide earlier 
treatment for patients with infarction have included mass 
public education about he symptoms ofmyocardial infarc- 
tion and prehospital administration f thrombolytic therapy. 
Phase 1 of the Myocardial Infarction Triage and Intervention 
trial (16) demonstrated the feasibility of patient selection by 
paramedics u ing a checklist of inclusion and exclusion 
criteria, a12 lead ECG transmitted bycellular telephone and 
remote consultation with an emergency room physician. I  
this Seattle study, it required only 52 min for the patient to 
recognize symptoms and for a paramedic toarrive at the 
scene. The paramedics required only 17 min to obtain a 
history and physical examination, transmit an ECG and start 
intravenous lines. The most striking finding was that even 
with prior knowledge of the transmitted ECG, the hospital 
evaluation required an additional 56 min. In the absence ofa 
transmitted ECG, the hospital evaluation required 76 min. 
Therefore, the major advantage of a paramedic system of 
delivering thrombolytic therapy is that it not only reduces 
the transport time, but also reduces the time wasted in most 
hospital emergency rooms. 
Risk of bleeding complications. Of all the complications of 
thrombolytic treatment, bleeding (particularly central ner- 
vous system hemorrhage) is the most feared. Therefore, 
several studies have attempted to identify conditions that 
predispose patients to an increased risk of bleeding. In- 
creased oses and a prolonged infusion of &PA have been 
associated with bleeding (42,43), as have hypertension a d 
IOW body weight in elderly women (44). These risk factors 
have been associated with an increased incidence ofbleeding 
primarily at the site of invasive procedures. However, few 
data exist with regard to bleeding complications in the 
absence of invasive procedures. 
Predisposing factors for intracranial hemorrhage. His- 
torically, contraindications for thrombolytic therapy were 
based on studies that identified risk factors for spontaneous 
hemorrhage. One of the largest series is that of Brott et al. 
(45), who reviewed I54 cases of spontaneous intracranial 
hemorrhage. They found that 46% of the patients were 
elderly, 45% had a history of hypertension a d 54% were 
hypertensive at the time of presentation. A prior cerebral 
event or neoplasm was present in 27% of cases. Despite an 
extensive evaluation f r potential risk factors, 41% of pa- 
tients had no predisposing conditions. 
In a Preliminary eport, O’Connor et al. (46) found a 0.7% 
incidence rate of intracranial bleeding in patients receiving 
r&P,4 with or without concomitant urokinase inthe Throm- 
bolysis and Angioplasty in Myocardial Infarction trial. The 
presence or absence of intracranial bleeding was compared 
with risk factors such as age, prior stroke, prior use of 
aspirin and hypertension. Although all five patients who had 
intracranial bleeding had at least one risk factor, so did 88% 
of patients with no evidence of intracranial bleeding. There- 
fore, it appears that currently accepted predisposing factors 
may not accurately identify patients at high risk of intracra- 
nial bleeding. 
Role of thrombolytic agent and dose. The risk of intra- 
cranial bleeding may, however, depend on the thrombolytic 
drug used and its dosage. Intravenous streptokinase therapy 
(31). anisoylated plasminogen str ptokinase activator com- 
plex (a), tissue plasminogen activator (Prolysis, Burroughs 
Wellcome) (47) and a 100 mg dose of rt-PA (Genentech) (43) 
are reported to have a similar incidence of intracranial 
bleeding. Thus, when used at the recommended dose, the 
thrombolytic agents are similar with regard to bleeding 
complications. However, with higher doses of rt-PA, such as 
the 150 mg dose used early in the TIMI-2B Study (43), a 
greater incidence of intracranial bleeding was observed 
(1.9%). For this reason, it is recommended that e 150 mg 
dose of &PA be abandoned. 
Thus, the potential risk of increased bleeding was of 
some concern when planning atrial of combination therapy 
using half dose rt-PA with full dose streptokinase at our 
institution (48). In this pilot study, there were no cases of 
intracranial bleeding; however, small patient numbers make 
the risk of intracranial bleeding difficult o ascertain. Fifteen 
percent of patients experienced serious bleeding complica- 
tions (primarily at the catheterization site) requiring transfu- 
sion. Thus, the prevalence and severity of bleeding compli- 
cations after low dose rt-PA and streptokinase were no 
greater than those r ported intrials employing acute angiog- 
raphy after t-PA alone (49). streptokinase alone (49) or the 
combination of rt-PA and urokinase (50). The lack of an 
increased incidence of bleeding in trials combining throm- 
bolytic drugs may relate to the lower dose and shorter 
infusion duration of rt-PA. 
Elderly patients. Elderly patients traditionally have been 
excluded from thrombolytic trials because of the perceived 
increased risk of intracranial hemorrhage. The mortality rate 
in older age groups is much greater than that in the overall 
group of patients with myocardial infarction (Table 6) (3-7). 
If one calculates the difference inthe mortality rate between 
placebo and treatment groups to determine lives saved per 
100 patients treated, it becomes apparent that the greatest 
potential benefit of thrombolytic therapy may be in the 
elderly. With the exception ofthe ntravenous Streptokinase 
in Acute Myocardial Infarction (ISAM) trial (3), which 
treated very few patients >70 years of age, the lifesaving 
potential for the elderly appears to be two to three times that 
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ct of Age in Previous Trials 
No. of Deaths (Q) 
Study 
lSAM (3) 
GPSSl (4) 
ISIS-II (7) 
ASSET (5) 
AIMS (6) 
Fooled 
Age (~0 Treatment 
<7Q 371728 (5.1) 
70-7s 171131 (13.0) 
<75 45715.268 (8.7) 
>75 171/592 (28.9) 
<7O 48216,897 (7.0) 
>7O 309/1,695 (18.2) 
<66 9211.71 I (5.4) 
66-75 901827 (10.8) 
<6S 211405 (5.2) 
65-70 11190 (12.2) 
Not elderly t.O89/15,009 (7.3) 
Elderly 59813.335 (17.9) 
Control Lives Saved* p Value 
48/726 (6.6) 1.5 0.21 
15/156 (9.6) -3.4 0.37 
55215,226 (10.6) 1.9 0.001 
2061623 (33. I) 4.2 0.11 
65916.879 (9.6) 2.6 0.0001 
37011.716 (21.6) 3.4 0.01 
10411.641 (6.3) 0.9 0.24 
1401852 (16.4) 5.6 O.OOP 
35141 I (8.5) 3.3 0.06 
26/86 (30.2) 1.8 0.003 
1.39W14.883 (9.4) 2.1 0.0001 
757j3.433 (22. I) 4.1 0.0001 
*Number of lives saved per IO0 patients treated (control group mortality - treatment group mortality). 
Abbreviations as in Tables I and 2. 
group. Pooled data from five trials (3-7) 
nificant reduction in mortality rate after 
17.9% compared with 
22.1% in control 01) (Table 6, Fig. 2). 
These elderly pat a worsened outcome 
from complications of tbrombolysis. Therefore, th se data 
suggest that advanced age in itself should not 
an absolute contraindication t  tbrombolytic 
siole, Although ypertension is a 
bleeding, a reduction i  mortalit 
thromboiytic herapy may offset his risk in t 
patient. The ISIS-II trial (7) reported the outcome of patients 
based on their blood pressure at the time of presentation. As 
demonstrated in that rial, patients normally excluded from 
thrombolytic trials because of the presence of cardiogenic 
shock experienced a reduced mortality rate after throm- 
bolytic therapy. Although “severe persistent hypertension” 
was a relative contraindication n that rial, among the I.141 
patients who presented with a systolic blood pressure > 175 
mm Hg, streptokinase therapy resulted in an improved 
mortality rate compared with placebo control (5.7% versus 
8.7%, respectively). Therefore, although ypertensive pa- 
tients may be at increased risk of intracranial bleeding, the 
mortality rate remains lower after treatment compared with 
that in patients in whom thrombolytic therapy is withheid. 
Available data suggest that only 10% of patients hospital- 
ized with the diagnosis of acute myocardial infarction i  the 
United States receive thrombolytic therapy. Mass public 
education, continuing medical education. drug administra- 
tion by paramedics and expanding inclusion criteria fob* 
tbrombolytic herapy are needed to increase :he number of 
patients treated. 
Given the data from recently published trials (5-7), indi- 
cations for tbrombo~ytic thera ould be reassessed (Table 
7). Patients who present with pain of >30 min duration 
with ST segment elevatio 
probably benefit from tbro 
eration should be given t 
dense for infarction whose EC& manifest left bundle 
braccb block. Although the time window for treatment 
remains controversial, it is clear that thrombolytic drugs 
should be routinely administered if 
within 6 b of symptom onset. Because 
suggest that patients may 
thrombolytic therapy sho
particularly if the patient is in a high risk subgroup, has 
stuttering onset of chest pain or evidence gf continued 
ischemia. Furthermore. th re are special subsets traditio 
Table 7. Selection Criteria for Thrombolytic Therapy 
Chest pain >30 min 
ECG 
ST elevation 
? LBBB 
Time window 
~6 h: routine treatment 
>6 h: high risk, continued chest pain 
Special subsets (benefit > risk) 
Elderly 
Moderate hypertension 
Hypotension 
Cardiopulmonary resuscitation 
Abbreviations as in Table 4. 
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ally excluded from thrombolytic herapy in whom the benefit 
may outweigh the risk. These include the elderly, patients 
who present with hypertension r shock and, as demon- 
strated in a recent report by Califf et al. (51). those who have 
undergone cardiopulmonary resuscitation. 
Although the indications for thrombolytic herapy should 
be expanded, given the lack of controlled scientific data, 
determination f risk/benefit ratio for a patient with one or 
more relative contraindications remains difficult. Until the 
results of the ongoing ISIS-III, delayed reperfusion and 
unstable angina trials are available, precise indications and 
contraindications for thrombolytic therapy remain uncer- 
tain. 
We acknowledge Lynne Comish for manuscript preparation. 
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